ANTIBODIES
Contributor Information
- Name Tuck-Weng Kok
- Institute The University of Adelaide
Tool Details
- Tool name: Anti-HIV Designer Antigen (DAG16)
- Alternate names: human immunodeficiency virus designer antigen
- Clone: DAG16
- Tool type: Antibodies
- Class: Polyclonal
- Conjugate: Unconjugated
- Reactivity: Human ; Guinea Pig ; Rat
- Host: Guinea Pig
- Application: ELISA ; IF ; WB
- Description: DAGs ĂÂdesigner antigensĂÂ carry epitopes that can lead to the elicitation of broadly neutralising antibodies (bNAbs) in HIV patients. Identification of effective epitopes is a key area of research as bNAbs are a consistent protective immune correlate in human immunodeficiency virus (HIV) patients as well as in passive immunotherapy studies.The DAG16,19 and 23 polyclonal antibodies lock onto epitopes on HIV pre-fusion intermediates. Lots of research focuses on identifying mAbs that target these pre-fusion intermediates, though this work has also identified some interest polyclonal antibodies that have shown to target pre-fusion epitopes and be useful tools in HIV research. The DAG16,19 and 23 have been used in experimentation to neutralise both T cell-tropic and macrophage-tropic HIV. The antibodies have been shown to be used to generate absorbed sera which contained antibodies against the viral DAG pre-fusion intermediates, but minimal or no antibodies against static/native HIV antigens and cellular antigens that are not involved in viral fusion. The antibodies have been shown to reduce T-cell tropic HIV-HXB2 infectivity by 65ĂÂ68% and, importantly, reduce macrophage-tropic HIV-Bal infectivity by 39ĂÂ46%. Please see publication (PMID: 25505973) for more details. Developing antibodies specific to novel epitopes on HIV pre-fusion intermediates is an incredibly important area of research and these polyclonals provide an interesting tool in this work. They have been shown to be instrumental in developing monoclonal antibodies specific to novel epitopes on HIV pre-fusion intermediates.
- Immunogen: HIV DAG 16
- Research area: Immunology; Microbiology
- For Research Use Only
Target Details
- Target: DAG16
- Target background: DAGs ÄËĂÂĂÂdesigner antigensÄËĂÂĂÂ carry epitopes that can lead to the elicitation of broadly neutralising antibodies (bNAbs) in HIV patients. Identification of effective epitopes is a key area of research as bNAbs are a consistent protective immune correlate in human immunodeficiency virus (HIV) patients as well as in passive immunotherapy studies.The DAG16,19 and 23 polyclonal antibodies lock onto epitopes on HIV pre-fusion intermediates. Lots of research focuses on identifying mAbs that target these pre-fusion intermediates, though this work has also identified some interest polyclonal antibodies that have shown to target pre-fusion epitopes and be useful tools in HIV research. The DAG16,19 and 23 have been used in experimentation to neutralise both T cell-tropic and macrophage-tropic HIV. The antibodies have been shown to be used to generate absorbed sera which contained antibodies against the viral DAG pre-fusion intermediates, but minimal or no antibodies against static/native HIV antigens and cellular antigens that are not involved in viral fusion. The antibodies have been shown to reduce T-cell tropic HIV-HXB2 infectivity by 65ÄËĂÂĂÂ68% and, importantly, reduce macrophage-tropic HIV-Bal infectivity by 39ÄËĂÂĂÂ46%. Please see publication (PMID: 25505973) for more details. Developing antibodies specific to novel epitopes on HIV pre-fusion intermediates is an incredibly important area of research and these polyclonals provide an interesting tool in this work. They have been shown to be instrumental in developing monoclonal antibodies specific to novel epitopes on HIV pre-fusion intermediates.
Application Details
- Application: ELISA ; IF ; WB
Handling
- Format: Liquid
- Shipping conditions: Shipping at 4Ă°C
Documentation
References
- • Kok et al. 2014. Clin Transl Immunology. 3(9):e24. PMID: 25505973.
.svg)
Unit size: 
.svg)
.svg)
